Mymetics Starts Research Project with Sanofi for Influenza Vaccines
Epalinges, December 1, 2016
Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics’ proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| 161201_Sanofi | Download |